Why choose a modular, automated approach to autologous CAR T manufacturing?

With over 10 commercially available therapies and more than 25,000 patients now treated, autologous CAR-T therapies have proven themselves in the clinic. However, significant challenges still face manufacturers, including high costs, frequent batch failures and delays, and traditional technologies that do not integrate well into advanced manufacturing workflows. This infographic provides insights and case study data demonstrating the benefits of a modular manufacturing approach, which helps to increase productivity by optimizing equipment usage. NEW INTERACTIVE FORMAT Listen to our expert speaker. Watch the video. Read the summary. Focus in on the data. Download the PDF. It has never been easier to quickly access the information you want. All in one place—at the click of a button.

Please enter your email to access content Read now